Molecular diagnostic POCT represents a future trend.
It is learned that Aoran Biotechnology (Shanghai) Co., Ltd. (hereinafter referred to as: Aoran Bio ) A round of financing of RMB 60 million has been completed. This round of financing was led by the latera medical and health industry fund, the first medical and health industry fund under Shenzhen Venture Capital. Earlier, Aoran Biological had obtained a round A investment of nearly 100 million yuan from Bangqin Capital in November 2016 and a strategic investment of 30 million yuan from Shanghai Kehua Biological Engineering Co., Ltd. in November 2017.
Ao Ran Biological was established in Shanghai International Medical Park in 2015, and has a R & D center in Guangzhou International Biological Island, with a R & D and production area of 3,000 square meters. It is a high-tech enterprise focusing on molecular diagnostic technology. We have developed a series of fully automated biological detectors, reagents and reagent smart boxes for the fields of microbial detection, personalized drug gene detection, cancer detection, forensic evidence, food safety and other fields.
The products developed by Aoran Bio have already applied for 64 patents and 42 have been authorized. Among them, 8 invention patents have been authorized, and 7 software copyrights have been obtained. The fluorescence PCR analysis system (Galaxy system) follows the development trend of the global molecular diagnostic “Sample-in, Results Out”.
It is reported that on May 16, 2018, Aoran Biotech officially signed a major project of the National “Thirteenth Five-Year Plan”. Its Galaxy Nano fully automatic qPCR machine and IGS TB / RIF Lite reagent products will participate in the evaluation. . In addition, Galaxy Nano and Orion independently developed by Aoran Bio have obtained EU CE certification, and Universal Nano has obtained three types of medical device registration certificates.
The data shows that compared with traditional products, the Galaxy system machine supporting reagents have the following advantages: only one minute is required to directly add the sample, and the nucleic acid extraction and detection are integrated and fully automated to obtain the final result; the sample detection is completely sealed To protect the biological safety of the experimental process; no special PCR laboratory is required to completely eliminate pollution; the detection process takes a short time, and only one to one and a half hours is required from the detection of the sample to the result report.
